Omada Health, Inc. (OMDA) Stock Price & Analysis
Omada Health, Inc. (OMDA) fell 3.16% to USD 20.53 as of July 25, 2026 at 03:03 UTC, according to Nexqual real-time market data.
OMDA last closed at USD 21.2; the session ranged USD 20.51–21.6 on volume of 1,166,118 shares. Market capitalization is $1.22B, with a 52-week range of USD 10.28–26.92 (NMS). Source: Nexqual, July 25, 2026 at 03:03 UTC.
Key Statistics (as of July 25, 2026 at 03:03 UTC)
| Price | USD 20.53 |
|---|---|
| Change | ▼ 3.16% (down) |
| Previous Close | USD 21.2 |
| Open | USD 21.5 |
| Day Range | USD 20.51 – 21.6 |
| 52-Week Range | USD 10.28 – 26.92 |
| Volume | 1,166,118 shares |
| Market Cap | $1.22B |
| Exchange | NMS |
Technical Analysis (OMDA)
Nexqual's technical model rates OMDA "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:03 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 41.21 (neutral) |
| vs SMA50 | Above (USD 19.49) |
| MACD | 0.76 (positive) |
Analyst Ratings (OMDA)
Wall Street analysts rate OMDA "Buy" based on 12 analysts, with a mean price target of USD 24.58 (range USD 15–30), per Nexqual as of July 25, 2026 at 03:03 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 24.58 |
| High Target | USD 30 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 10 / 2 / 0 |
Earnings (OMDA)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.06 |
| Revenue Estimate | $80.06M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.05 vs est -0.04 ▲ beat |
| 2025-12-31 | USD 0.16 vs est 0.03 ▲ beat |
| 2025-09-30 | USD 0.03 vs est -0.07 ▲ beat |
| 2025-06-30 | USD -0.05 vs est -0.13 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financials & Fundamentals (OMDA)
| Total Revenue | $283.30M |
|---|---|
| Revenue Growth (YoY) | +42.00% |
| Gross Margin | +66.27% |
| Operating Margin | -6.13% |
| Profit Margin | -2.22% |
| ROE | -4.30% |
| Current Ratio | 3.92 |
| Total Cash | $211.76M |
| Total Debt | $0 |
| Free Cash Flow | $16.81M |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financial Health Score (OMDA)
Nexqual rates Omada Health, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:03 UTC.
| Growth | Strong — Revenue +42% YoY (latest Q) |
|---|---|
| Profitability | Solid — Gross margin 66%, operating -6% |
| Balance Sheet | Mixed — $212M cash, no debt |
| Cash Flow | Solid — FCF $17M, 6% margin |
| Efficiency | Critical — ROE -4%, ROA -2.4% |
Ownership (OMDA)
| Insider Ownership | +2.18% |
|---|---|
| Institutional Ownership | +81.79% |
| Shares Outstanding | 59.45M |
| Float | 46.64M |
| Short % of Float | +13.36% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Leadership (OMDA)
Omada Health, Inc. is led by Sean P. Duffy (age 41), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 03:03 UTC.
| Co-Founder, CEO & Director | Sean P. Duffy (age 41) |
|---|---|
| President | Wei-Li Shao (age 54) |
| Chief Financial Officer | Steven L. Cook (age 39) |
| Senior Vice President of Corporate Strategy & Operations | Lauren Fix |
| Chief Technology Officer | Sunil Kayiti |
Major Backers & Investors (OMDA)
Notable institutional backers of Omada Health, Inc. include Divisadero Street Capital Management, LP, Revelation Capital Management, LLC, American Century Companies Inc, according to Nexqual as of July 25, 2026 at 03:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Divisadero Street Capital Management, LP | 9.9% |
| Revelation Capital Management, LLC | 8.76% |
| American Century Companies Inc | 7.87% |
| Cigna Investments Inc/New | 5.79% |
| FMR, LLC | 5.53% |
| LOOMIS SAYLES & CO L P | 4.49% |
| NVP Associates, LLC | 4.26% |
| a16z Capital Management, L.L.C. | 3.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.85% |
| BlackRock | 4.81% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
From Omada Health, Inc.'s Latest SEC 10-K Filing (filed 2026-03-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services ("HHS") may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.
- Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA's General Controls for medical devices, which include compliance with the applicable portions of the Quality Management System Regulation ("QMSR"), facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials.
- As of December 31, 2025, we had more than 2,000 customers, over 886,000 total members enrolled in one or more programs, and had supported nearly two million members since launch.
- We Deliver Outcome s: We have demonstrated clinical outcomes and economic value across our multi- condition platform, including 30 published, peer-reviewed studies as of December 31, 2025, which allow us to improve our programs and serve as a key differentiator.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HNGE | Hinge Health, Inc. | USD 74.31 | ▼ 6.03% |
| CHYM | Chime Financial, Inc. | USD 20.69 | ▼ 5.18% |
| ETOR | eToro Group Ltd. | USD 36.78 | ▼ 1.97% |
| MNTN | MNTN, Inc. | USD 8.58 | ▲ 0.12% |
| HROW | Harrow, Inc. | USD 38.45 | ▼ 10.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:03 UTC. This page is informational and not investment advice.